Ivacaftor

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:FDA
January 31, 2012
gptkbp:availability prescription only
gptkbp:bioavailability approximately 50%
gptkbp:brand gptkb:Kalydeco
gptkbp:chemical_formula C24 H28 Cl N3 O3 S
gptkbp:class gptkb:Cystic_fibrosis_transmembrane_conductance_regulator_(CFTR)_modulators
gptkbp:clinical_trial Phase 3
VX-770-101
VX-770-102
VX-770-103
VX-770-104
gptkbp:clinical_use long-term treatment
gptkbp:composed_by gptkb:chemical_compound
gptkbp:contraindication severe liver impairment
gptkbp:discovered_by gptkb:Vertex_Pharmaceuticals
gptkbp:dosage_form tablets
gptkbp:excretion bile
gptkbp:formulation film-coated tablets
https://www.w3.org/2000/01/rdf-schema#label Ivacaftor
gptkbp:indication G551 D mutation in CFTR gene
gptkbp:ingredients gptkb:Ivacaftor
gptkbp:interacts_with strong CYP3 A inducers
strong CYP3 A inhibitors
gptkbp:invention patented
gptkbp:lifespan approximately 12 hours
gptkbp:marketed_as gptkb:Canada
gptkb:European_Union
gptkb:United_States
gptkbp:mechanism_of_action potentiator of CFTR
gptkbp:metabolism liver
gptkbp:patient_population children and adults
gptkbp:pharmacokinetics variable absorption
increases chloride transport
gptkbp:price high
gptkbp:provides_guidance_on Cystic Fibrosis Foundation guidelines
gptkbp:regulatory_compliance gptkb:Health_Canada
gptkb:EMA
TGA
gptkbp:research_focus gptkb:CFTR_modulators
gptkbp:rounds urine
gptkbp:route_of_administration oral
gptkbp:safety_features generally well tolerated
gptkbp:side_effect dizziness
fatigue
headache
nausea
abdominal pain
diarrhea
rash
upper respiratory tract infection
liver function abnormalities
gptkbp:storage room temperature
gptkbp:targets CFTR protein
gptkbp:type_of_care important for efficacy
gptkbp:used_for gptkb:cystic_fibrosis
gptkbp:bfsParent gptkb:Symdeko
gptkb:CFTR_modulators
gptkbp:bfsLayer 5